Based on the information available, I can confirm that Apotex, a Canadian pharmaceutical company, filed a U.S. Abbreviated New Drug Application (ANDA) for a generic version of Incyte's ruxolitinib, a drug used to treat certain types of blood cancer [1]. According to the information provided by DrugPatentWatch.com, Apotex submitted this filing on October 2, 2020 [1]. This filing is for the 5 mg, 10 mg, 15 mg, and 20 mg dosage forms of ruxolitinib, which are currently available under the brand name Jakafi [1].

It is important to note that the approval of this ANDA by the U.S. Food and Drug Administration (FDA) is still pending [1]. If approved, Apotex's generic ruxolitinib would be the first generic version of Jakafi available in the U.S. market [1].

**Sources:**

[1] DrugPatentWatch.com. (n.d.). Ruxolitinib (Jakafi) - Patent Expiration & Generic Entry. Retrieved from <https://www.drugpatentwatch.com/drugs/ruxolitinib>